Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat diabetic macular edema (DME) With as few as two treatments per year, Susvimo may help people with DME maintain their vision Approval marks the second indication for Susvimo in addition to wet, or neovascular age-related macular [Read More]
Category: Research and Developments
Where Are We Now?
A Summary of the Past 30 Years of Low Vision Research and Development (An update presented to the International Low Vision Support Group by Director Dan Roberts) Macular Degeneration Support’s International Low Vision Support Group will soon celebrate its 30th year as a leading outreach to people affected by macular degeneration and other diseases leading [Read More]
FDA Approval Brings Long Awaited Hope to Patients With Geographic Atrophy
by Jeff Todd, President + CEO at Prevent Blindness And just like that, the landscape for vision loss and blindness has shifted dramatically! For years, millions of people around the world who are living with an untreatable and potentially blinding condition, along with their care partners, have been waiting with hopeful anticipation for a treatment [Read More]
New Study Finds Higher Prevalence of Age-Related Macular Degeneration (AMD) Cases than Previously Determined and a High Degree of County Variation
A new study “The Prevalence of Age-Related Macular Degeneration in the United States In 2019” published in JAMA Ophthalmology, found that in 2019, there were an estimated 19.83 million Americans were living with some form of age-related macular degeneration (AMD) in 2019. This is an increase of approximately more than 2.75 times previous estimates (which used a more [Read More]
Susvimo implant for Wet AMD Voluntarily Recalled
Susvimo, previously called Port Delivery System with ranibizumab (Lucentis), was FDA-approved on October 21, 2021, for intravitreal use via ocular implant for the treatment of people with wet (neovascular) age-related macular degeneration (AMD). Now, one year later, Genentech has announced that it is voluntarily recalling the implant and the insertion tool in the U.S. As [Read More]